浸润性膀胱癌新辅助化疗的研究进展
|
摘要
浸润性膀胱癌较易出现微转移灶,单纯手术治疗效果不佳、复发率较高。新辅助化疗可以彻底清除近处微转移灶及远处大面积转移,提高患者生存期。新辅助化疗疗效确切,目前大量专家学者正在进行大量研究探索,希望获得更为标准的新辅助化疗方案。本文将浸润性膀胱癌新辅助化疗的研究进展作一综述。
Invasive bladder cancer is more prone to micrometastases. Surgery alone is not effective and has a high recurrence rate.Neoadjuvant chemotherapy can completely remove the near micrometastases and large distant metastases, and improve the survival of patients. Neoadjuvant chemotherapy has a definite curative effect. At present, a large number of experts and scholars are conducting a lot of research and exploration, hoping to obtain a more standard neoadjuvant chemotherapy program. This article reviews the research progress of neoadjuvant chemotherapy for invasive bladder cancer.
Invasive bladder cancer is more prone to micrometastases. Surgery alone is not effective and has a high recurrence rate.Neoadjuvant chemotherapy can completely remove the near micrometastases and large distant metastases, and improve the survival of patients. Neoadjuvant chemotherapy has a definite curative effect. At present, a large number of experts and scholars are conducting a lot of research and exploration, hoping to obtain a more standard neoadjuvant chemotherapy program. This article reviews the research progress of neoadjuvant chemotherapy for invasive bladder cancer.
引文
[1]Alfred W J,Lebret T,Compérat E M,et al.Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer[J].European Urology,2017,71(3):462-475.
[2]翟建坡,王建伟,王海东,等.肌层浸润性膀胱癌的新辅助化疗研究进展[J].肿瘤防治研究,2014,41(10):1129-1133.
[3]Kawamura N,Matsushita M,Okada T,et al.Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate,vinblastine,adriamycin,and cisplatin in the management for muscle-invasive bladder cancer[J].Hinyokika Kiyo Acta Urologica Japonica,2013,59(5):277-81.
[4]朱熹,田野.评估膀胱癌新辅助化疗效果的生物标志物研究进展[J].中华泌尿外科杂志,2015(6):475-477.
[5]Herr H W,Bajorin D F.Can p53 help select patients with invasive bladder cancer for bladder preservation?[J].Journal of Urology,1999,161(1):20-22.
[6]Pflaum,Johanna,Schlosser,Sophie,Müller,Martina.p53 Family and Cellular Stress Responses in Cancer[J].Front Oncol,2014,4(3):285-300.
[7]Andre F,Arnedos M,Goubar A,et al.Ki67-no evidence for its use in nodepositive breast cancer[J].Nature Reviews Clinical Oncology,2015,12(5):296-301.
[8]Grossman H B,Tangen C M,Cordon-Cardo C,et al.Evaluation of Ki67,p53and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy:a Southwest Oncology Group Study[J].Oncology Reports,2006,16(4):807-810.
[9]Sikov W M.Assessing the role of platinum agents in aggressive breast cancers[J].Current Oncology Reports,2015,17(2):1-10.
[10]Font A,Taron M,Gago J L,et al.BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer[J].Annals of Oncology Official Journal of the European Society for Medical Oncology,2011,22(1):139-144.
[11]Slaton JW,Millikan R,Inoue K,et al.Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy[J].The Journal of Urology,2004,171(2):570-574.
[12]Kawashima A,Nakayama M,Kakuta Y,et al.Excision repair crosscomplementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer[J].Clinical Cancer Research,2011,17(8):2561-2569.
[13]Ozcan M F,Dizdar O,Dincer N,et al.Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinumbased neoadjuvant chemotherapy[J].Urologic Oncology Seminars&Original Investigations,2013,31(8):1709-1715.
[14]Allen E M V,Mouw K W,Kim P,et al.Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma[J].Cancer Discovery,2014,4(10):1140-1153.
[15]蒋召强,徐鑫,孙恒,等.肌层浸润性膀胱癌经典新辅助化疗方案的进展[J].国际泌尿系统杂志,2016,36(1):122-125.
[16]Pliarchopoulou K,Laschos K,Pectasides D.Current chemotherapeutic options for the treatment of advanced bladder cancer:a review[J].Urologic Oncology Seminars&Original Investigations,2013,31(3):294-302.
[17]Viens P,Gravis G,Bladou F,et al.Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate,vinblastine,doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma[J].European Cytokine Network,1996,7(3):395-399.
[18]Meeks J J,Bellmunt J,Bochner B H,et al.A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer[J].European Urology,2012,62(3):523-533.
[19]Blick C,Hall P,Pwint T,et al.Accelerated methotrexate,vinblastine,doxorubicin,and cisplatin(AMVAC)as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder[J].Cancer,2012,118(16):3920-3927.
[20]Plimack E R,Hoffmancensits J H,Viterbo R,et al.Accelerated methotrexate,vinblastine,doxorubicin,and cisplatin is safe,effective,and efficient neoadjuvant treatment for muscle-invasive bladder cancer:results of a multicenter phase II study with molecular correlates of response and toxicity[J].Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology,2014,32(18):1895-1901.
[21]Chism D D,Woods M E,Milowsky M I.Neoadjuvant paradigm for accelerated drug development:an ideal model in bladder cancer[J].Oncologist,2013,18(8):933-940.
[22]Zargar H,Espiritu P N,Fairey A S,et al.Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer[J].European Urology,2015,67(2):241-249.
[23]Griffiths G,Hall R,Sylvester R,et al.International phase III trial assessing neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer:long-term results of the BA06 30894 trial[J].J Urol,2011,29(16):1063-1064.
[24]Iwasaki K,Obara W,Kato Y,et al.Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer[J].Japanese Journal of Clinical Oncology,2013,43(2):193-199.
[25]Koie T,Ohyama C,Hashimoto Y,et al.Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer,including those unfit for cisplatin:a prospective single-arm study[J].International Journal of Clinical Oncology,2013,18(4):724-730.
[26]Mossanen M,Lee F,Cheng H,et al.Nonresponse to neoadjuvant chemotherapy for muscle-invasive urothelial cell carcinoma of the bladder[J].Clinical Genitourinary Cancer,2014,12(3):210-213.
[2]翟建坡,王建伟,王海东,等.肌层浸润性膀胱癌的新辅助化疗研究进展[J].肿瘤防治研究,2014,41(10):1129-1133.
[3]Kawamura N,Matsushita M,Okada T,et al.Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate,vinblastine,adriamycin,and cisplatin in the management for muscle-invasive bladder cancer[J].Hinyokika Kiyo Acta Urologica Japonica,2013,59(5):277-81.
[4]朱熹,田野.评估膀胱癌新辅助化疗效果的生物标志物研究进展[J].中华泌尿外科杂志,2015(6):475-477.
[5]Herr H W,Bajorin D F.Can p53 help select patients with invasive bladder cancer for bladder preservation?[J].Journal of Urology,1999,161(1):20-22.
[6]Pflaum,Johanna,Schlosser,Sophie,Müller,Martina.p53 Family and Cellular Stress Responses in Cancer[J].Front Oncol,2014,4(3):285-300.
[7]Andre F,Arnedos M,Goubar A,et al.Ki67-no evidence for its use in nodepositive breast cancer[J].Nature Reviews Clinical Oncology,2015,12(5):296-301.
[8]Grossman H B,Tangen C M,Cordon-Cardo C,et al.Evaluation of Ki67,p53and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy:a Southwest Oncology Group Study[J].Oncology Reports,2006,16(4):807-810.
[9]Sikov W M.Assessing the role of platinum agents in aggressive breast cancers[J].Current Oncology Reports,2015,17(2):1-10.
[10]Font A,Taron M,Gago J L,et al.BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer[J].Annals of Oncology Official Journal of the European Society for Medical Oncology,2011,22(1):139-144.
[11]Slaton JW,Millikan R,Inoue K,et al.Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy[J].The Journal of Urology,2004,171(2):570-574.
[12]Kawashima A,Nakayama M,Kakuta Y,et al.Excision repair crosscomplementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer[J].Clinical Cancer Research,2011,17(8):2561-2569.
[13]Ozcan M F,Dizdar O,Dincer N,et al.Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinumbased neoadjuvant chemotherapy[J].Urologic Oncology Seminars&Original Investigations,2013,31(8):1709-1715.
[14]Allen E M V,Mouw K W,Kim P,et al.Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma[J].Cancer Discovery,2014,4(10):1140-1153.
[15]蒋召强,徐鑫,孙恒,等.肌层浸润性膀胱癌经典新辅助化疗方案的进展[J].国际泌尿系统杂志,2016,36(1):122-125.
[16]Pliarchopoulou K,Laschos K,Pectasides D.Current chemotherapeutic options for the treatment of advanced bladder cancer:a review[J].Urologic Oncology Seminars&Original Investigations,2013,31(3):294-302.
[17]Viens P,Gravis G,Bladou F,et al.Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate,vinblastine,doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma[J].European Cytokine Network,1996,7(3):395-399.
[18]Meeks J J,Bellmunt J,Bochner B H,et al.A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer[J].European Urology,2012,62(3):523-533.
[19]Blick C,Hall P,Pwint T,et al.Accelerated methotrexate,vinblastine,doxorubicin,and cisplatin(AMVAC)as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder[J].Cancer,2012,118(16):3920-3927.
[20]Plimack E R,Hoffmancensits J H,Viterbo R,et al.Accelerated methotrexate,vinblastine,doxorubicin,and cisplatin is safe,effective,and efficient neoadjuvant treatment for muscle-invasive bladder cancer:results of a multicenter phase II study with molecular correlates of response and toxicity[J].Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology,2014,32(18):1895-1901.
[21]Chism D D,Woods M E,Milowsky M I.Neoadjuvant paradigm for accelerated drug development:an ideal model in bladder cancer[J].Oncologist,2013,18(8):933-940.
[22]Zargar H,Espiritu P N,Fairey A S,et al.Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer[J].European Urology,2015,67(2):241-249.
[23]Griffiths G,Hall R,Sylvester R,et al.International phase III trial assessing neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer:long-term results of the BA06 30894 trial[J].J Urol,2011,29(16):1063-1064.
[24]Iwasaki K,Obara W,Kato Y,et al.Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer[J].Japanese Journal of Clinical Oncology,2013,43(2):193-199.
[25]Koie T,Ohyama C,Hashimoto Y,et al.Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer,including those unfit for cisplatin:a prospective single-arm study[J].International Journal of Clinical Oncology,2013,18(4):724-730.
[26]Mossanen M,Lee F,Cheng H,et al.Nonresponse to neoadjuvant chemotherapy for muscle-invasive urothelial cell carcinoma of the bladder[J].Clinical Genitourinary Cancer,2014,12(3):210-213.